Agomab Reports Positive STENOVA Data For Ontunisertib
(RTTNews) - On Thursday, Agomab Therapeutics (AGMB) reported positive results from the 48-week open-label extension of the Phase 2a STENOVA study evaluating ontunisertib in patients with fibrostenosing Crohn's disease.